Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-27T22:58:43.288Z Has data issue: false hasContentIssue false
  • English
  • Français

Prolactin responses to im haloperidol in drug-naive and drug-experienced schizophrenic patients

Published online by Cambridge University Press:  16 April 2020

M Markianos ,
A Botsis ,
J Hatzimanolis  and
C Stefanis
M Markianos
Affiliation:
Athens University Medical School, Psychiatric Clinic, Eginition Hospital and University Research Institute for Mental Health, Vas Sophias 74, 11528Athens, Greece
A Botsis
Affiliation:
Athens University Medical School, Psychiatric Clinic, Eginition Hospital and University Research Institute for Mental Health, Vas Sophias 74, 11528Athens, Greece
J Hatzimanolis
Affiliation:
Athens University Medical School, Psychiatric Clinic, Eginition Hospital and University Research Institute for Mental Health, Vas Sophias 74, 11528Athens, Greece
C Stefanis
Affiliation:
Athens University Medical School, Psychiatric Clinic, Eginition Hospital and University Research Institute for Mental Health, Vas Sophias 74, 11528Athens, Greece
Get access

Summary

The prolactin (PRL) responses to 5 mg im haloperidol were assessed in the drug-free state and after one month treatment with neuroleptics in 14 male schizophrenic patients who had never received drug treatment, and in 20 male patients who had discontinued their neuroleptic treatment for periods of two months to one year. Drug experienced patients showed lower PRL increases after acute haloperidol (mean 31.7 ng/ml) than drug-naive patients (mean responses 43.4 ng/ml). After treatment with neuroleptics in doses appropriate for the best clinical response, the baseline PRL levels were similar in the two groups, and im haloperidol did not cause any further PRL increases. The results provide evidence that after discontinuation of neuroleptics, the hypothalamic-pituitary dopamine receptors are subsensitive, and remain in that state for long periods of time.

Keywords

schizophreniadrug naive patientshaloperidolprolactin
Type
Original article
Information
European Psychiatry , Volume 9 , Issue 2 , 1994 , pp. 91 - 94
Copyright
Copyright © European Psychiatric Association 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Burt, DRCreese, ISnyder, SH. Antischizophrenic drugs: chronic treatment elevated dopamine receptor binding in brain. Science 1977;196:326-8CrossRefGoogle Scholar
Ettig, PNair, NPVLal, SCervantes, PGuyda, H. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J Neurol Neurosurg Psychiatry 1976;39:870-6CrossRefGoogle Scholar
Farde, LWiesel, FAStone-Elander, SHalldin, CNordstrom, ALHall, HSedvall, G. D2 Dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatr 1990;47:213-9CrossRefGoogle ScholarPubMed
Green, AIFaraone, SVBrown, WA. Prolactin shifts after neuroleptic withdrawal. Psychiatr Res 1990;32:213-9CrossRefGoogle ScholarPubMed
Gruen, PHSachar, EJLanger, GAltman, NLeifer, MFrantz, AHalpern, FS. Prolactin responses to neuroleptics in normal and schizophrenic patients. Arch Gen Psychiatr 1978;35:108-16CrossRefGoogle Scholar
Hays, SERubin, RT. Differential prolactin responses to haloperidol and TRH in normal adult men. Psychoneuroendocrinol 1981;6:45–52CrossRefGoogle ScholarPubMed
Keks, NACopolov, DLSingh, BS. Abnormal prolactin responses to haloperidol challenge in men with schizophrenia. Am J Psychiatry 1987;144:1335-7Google Scholar
Kirkpatrick, BBuchanan, RWMaeda, KCarpenter, WTJauch, DTamminga, TI. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation. Biol Psychiatry 1989;26:131-8CrossRefGoogle ScholarPubMed
Kolakowska, TBraddock, LWiles, DFranklin, MGelder, M. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge. Br J Psychiatr 1981;139:400-4CrossRefGoogle ScholarPubMed
Kornhuher, JRiederer, PReynolds, GPBeckmann, HJellinger, KGabriel, E. 3H-spiperone binding in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989;75:1–10CrossRefGoogle Scholar
Lynch, MR. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol. Neuropsychobiology 1990;24:102-8CrossRefGoogle ScholarPubMed
Mackay, AVPIversen, IIRossor, MSpokes, EBird, EArregui, ACreese, ISnyder, SH. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatr 1982;39:991-7CrossRefGoogle Scholar
Markianos, MSakellariou, GBistolaki, F. Prolactin responses to haloperidol in drug-free and treated schizophrenic patients. J Neural Transm 1991;83:37–42CrossRefGoogle ScholarPubMed
Meltzer, HYBusch, D. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Psychiatry Res 1979;9:285-99CrossRefGoogle Scholar
Muller-Spahn, FAckenheil, MAlbus, MMay, GNaber, DWelter, DZander, K. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia. Psychopharmacology 1984;84:436-40CrossRefGoogle ScholarPubMed
Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52CrossRefGoogle ScholarPubMed
Wong, DFWagner, HNTune, LEet al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.